Michael Girschikofsky

4.9k total citations · 1 hit paper
33 papers, 2.1k citations indexed

About

Michael Girschikofsky is a scholar working on Hematology, Infectious Diseases and Oncology. According to data from OpenAlex, Michael Girschikofsky has authored 33 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 9 papers in Infectious Diseases and 9 papers in Oncology. Recurrent topics in Michael Girschikofsky's work include Acute Myeloid Leukemia Research (9 papers), Antifungal resistance and susceptibility (4 papers) and Parvovirus B19 Infection Studies (4 papers). Michael Girschikofsky is often cited by papers focused on Acute Myeloid Leukemia Research (9 papers), Antifungal resistance and susceptibility (4 papers) and Parvovirus B19 Infection Studies (4 papers). Michael Girschikofsky collaborates with scholars based in Austria, Germany and United States. Michael Girschikofsky's co-authors include Kenneth L. McClain, Maurizio Aricò, Michael B. Jordan, Kim E. Nichols, Ashish Kumar, Tatiana von Bahr Greenwood, Paul La Rosée, Jan‐Inge Henter, Jan van Laar and Cesare Danesino and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Michael Girschikofsky

30 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Recommendations for the management of hemophagocytic lymphohistiocytosis in adults

2019 598 citations Paul La Rosée, AnnaCarin Horne et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Girschikofsky Austria	15	900	789	645	638	447	33	2.1k
Kazuko Kudo Japan	30	503 0.6×	1.3k 1.7×	439 0.7×	406 0.6×	357 0.8×	102	2.4k
David Boutboul France	26	419 0.5×	578 0.7×	213 0.3×	964 1.5×	203 0.5×	91	2.2k
Masahiro Sako Japan	32	673 0.7×	1.8k 2.3×	189 0.3×	1.0k 1.6×	154 0.3×	78	2.8k
Julián Sevilla Spain	26	297 0.3×	1.2k 1.5×	181 0.3×	640 1.0×	171 0.4×	130	2.3k
Marion Malphettes France	20	249 0.3×	317 0.4×	149 0.2×	840 1.3×	139 0.3×	60	1.7k
Michele Paessler United States	17	256 0.3×	824 1.0×	93 0.1×	943 1.5×	291 0.7×	56	2.0k
Andishe Attarbaschi Austria	33	422 0.5×	1.1k 1.5×	139 0.2×	327 0.5×	138 0.3×	155	3.4k
Bimba F. Hoyer Germany	24	242 0.3×	324 0.4×	117 0.2×	1.6k 2.6×	129 0.3×	69	2.7k
Neena Kapoor United States	24	274 0.3×	1.3k 1.6×	103 0.2×	1.2k 1.9×	164 0.4×	83	2.8k
Nathalie Parquet France	21	222 0.2×	449 0.6×	131 0.2×	281 0.4×	71 0.2×	55	1.4k

Countries citing papers authored by Michael Girschikofsky

Since Specialization

Citations

This map shows the geographic impact of Michael Girschikofsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Girschikofsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Girschikofsky more than expected).

Fields of papers citing papers by Michael Girschikofsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Girschikofsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Girschikofsky. The network helps show where Michael Girschikofsky may publish in the future.

Co-authorship network of co-authors of Michael Girschikofsky

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Girschikofsky. A scholar is included among the top collaborators of Michael Girschikofsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Girschikofsky. Michael Girschikofsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Buxhofer‐Ausch, Veronika, Sigrid Machherndl‐Spandl, Michaela Binder, et al.. (2023). Successful SARS-CoV-2 mRNA Vaccination Program in Allogeneic Hematopoietic Stem Cell Transplant Recipients—A Retrospective Single-Center Analysis. Vaccines. 11(10). 1534–1534. 2 indexed citations

Machherndl‐Spandl, Sigrid, Veronika Buxhofer‐Ausch, Michaela Binder, et al.. (2023). Allogeneic Stem Cell Transplantation in Multiple Myeloma: Risk Factors and Outcomes in the Era of New Therapeutic Options—A Single-Center Experience. Cancers. 15(24). 5738–5738. 2 indexed citations

Panje, Cédric, Stefanie Hayoz, Wolfgang Eisterer, et al.. (2022). Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trial. European Journal of Cancer. 177. 186–193. 2 indexed citations

Rosée, Paul La, AnnaCarin Horne, Melissa Hines, et al.. (2019). Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 133(23). 2465–2477. 598 indexed citations breakdown →

Egle, Alexander, Michael Steurer, Thomas Melchardt, et al.. (2018). Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study. Annals of Hematology. 97(10). 1825–1839. 9 indexed citations

Ruhstaller, Thomas, Peter Thuss‐Patience, Stefanie Hayoz, et al.. (2017). Intergroup phase III trial of neo-adjuvant chemotherapy, followed by chemoradiation and surgery with and without cetuximab in locally advanced esophageal carcinoma: First results from the SAKK 75/08 trial.. Journal of Clinical Oncology. 35(15_suppl). 4019–4019. 4 indexed citations

Springer, Jan, Michaela Lackner, David Nachbaur, et al.. (2015). Prospective multicentre PCR-based Aspergillus DNA screening in high-risk patients with and without primary antifungal mould prophylaxis. Clinical Microbiology and Infection. 22(1). 80–86. 55 indexed citations

Greil, Richard, Werner Linkesch, Thomas Nösslinger, et al.. (2015). Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria. Clinical Lymphoma Myeloma & Leukemia. 15(11). e143–e149. 1 indexed citations

Pleyer, Lisa, Ulrich Germing, Wolfgang R. Sperr, et al.. (2014). Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. Leukemia Research. 38(4). 475–483. 44 indexed citations

10.

Pleyer, Lisa, Sonja Burgstaller, Michael Girschikofsky, et al.. (2014). Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. Annals of Hematology. 93(11). 1825–1838. 62 indexed citations

11.

Ploner, Ferdinand, Thomas Bauernhofer, Wolfgang Hilbe, et al.. (2014). Sorafenib in advanced, heavily pretreated patients with soft tissue sarcomas. Anti-Cancer Drugs. 25(7). 848–853. 7 indexed citations

12.

Girschikofsky, Michael, Maurizio Aricò, Diego Castillo, et al.. (2013). Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet Journal of Rare Diseases. 8(1). 72–72. 209 indexed citations

13.

Pleyer, Lisa, Reinhard Stauder, Sonja Burgstaller, et al.. (2011). Activity of Azacitidine in 26 Unselected, Consecutive CMML Patients Included in the Austrian Azacitidine Registry (AAR) of the AGMT-Study Group. Blood. 118(21). 1715–1715. 1 indexed citations

14.

Perkhofer, Susanne, Cornelia Lass‐Flörl, Michaela M. Hell, et al.. (2010). The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients. International Journal of Antimicrobial Agents. 36(6). 531–536. 79 indexed citations

15.

Sperr, Wolfgang R., Michael Kundi, Michael Girschikofsky, et al.. (2009). Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology. European Journal of Clinical Investigation. 39(10). 914–923. 66 indexed citations

16.

Zach, Otto, Otto Krieger, H. Kasparu, et al.. (2008). A single nucleotide polymorphism at chromosome 2q21.3 (LCT −13910C>T) associates with clinical outcome after allogeneic hematopoietic stem cell transplantation. Blood. 112(5). 2156–2159. 1 indexed citations

17.

Sperr, Wolfgang R., Michael Girschikofsky, Stefan Winkler, et al.. (2006). Diagnostic and Prognostic Significance of Tryptase in Clinical Hematology: A Single Center Experience from 1070 Patients.. Blood. 108(11). 2316–2316.

18.

Aricò, Maurizio, Michael Girschikofsky, T Généreau, et al.. (2003). Langerhans cell histiocytosis in adultsReport from the International Registry of the Histiocyte Society. European Journal of Cancer. 39(16). 2341–2348. 343 indexed citations

19.

Olipitz, Werner, Georg Hopfinger, Ricardo C.T. Aguiar, et al.. (2002). Defective DNA‐mismatch repair: a potential mediator of leukemogenic susceptibility in therapy‐related myelodysplasia and leukemia. Genes Chromosomes and Cancer. 34(2). 243–248. 28 indexed citations

20.

Krieger, O., H. Kasparu, Michael Girschikofsky, et al.. (1997). 181 Cladribine (2-CDA) is active in “high-risk”-chronic myelomonocytic leukemia and secondary or relapsed acute myelo(Mono)cytic leukemia. Leukemia Research. 21(1). S48–S48. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact